Results 61 to 70 of about 434,636 (318)

Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways [PDF]

open access: yes, 2015
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer, it remains a huge challenge to understand the cellular and molecular mechanisms of the aggressive behavior of EOC cells.
Armstrong   +51 more
core   +1 more source

A Multi-marker Model for Predicting Decompensated Heart Failure in Patients with Prior Acute Myocardial Infarction [PDF]

open access: yes, 2020
The aim of the study was to assess the prognostic value of determining the plasma concentration of NT-proBNP and ST2 in the patients with decompensated HF and prior acute myocardial infarction and their combination in this category of patients.Materials ...
Levandovska, K. (Khrystyna)
core   +3 more sources

Red Blood Cells Store and Release Interleukin-33 [PDF]

open access: yesJournal of Investigative Medicine, 2015
Interleukin-33 (IL-33) is a member of the IL-1 cytokine superfamily that potently drives production of a variety of cytokines and contributes to the pathogenesis of inflammatory diseases. The IL-33 is a nuclear protein and is released from apoptotic or necrotic cells.
Jianxin, Wei   +6 more
openaire   +2 more sources

The early transcriptomic response to interleukin 1β and interleukin 33 in rat neonatal cardiomyocytes [PDF]

open access: yes, 2013
In the heart, inflammatory cytokines including interleukin (IL) 1β are implicated in regulating adaptive and maladaptive changes, whereas IL33 negatively regulates cardiomyocyte hypertrophy and promotes cardioprotection.
Barrett, Oliver P T   +4 more
core   +1 more source

Association between pro-inflammatory cytokine interleukin-33 and periodontal disease in the elderly: A retrospective study

open access: yesJournal of Indian Society of Periodontology, 2017
Background: Senescence is a multifactorial process that in humans may be accompanied by inflammation and immune dysfunction in the oral cavity. Notably, periodontal disease, considered one of the most common inflammatory disorders in the oral cavity, has
Wellington Francisco Rodrigues   +4 more
doaj   +1 more source

Comparation between serum levels of interleukin-33 in children with allergic asthma before and after inhalatory corticosteroid treatment [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo, 2020
Introduction/Objective. Interleukin 33 (IL-33) has a very significant function in inflammatory and autoimmune mechanisms, but its significance in immunopathogenic mechanisms of different allergic diseases, including allergic asthma (AA), is becoming ...
Milanović Borko   +3 more
doaj   +1 more source

Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease [PDF]

open access: yes, 2017
IgG4-related disease (IgG4-RD) is characterized by elevated serum IgG4 and marked infiltration of IgG4-positive cells in multiple organs. Interleukin-33 (IL-33) is a recently described cytokine that is secreted by damaged epithelial cells, macrophages ...
Furukawa Sachiko   +14 more
core   +1 more source

Interleukin-33 and ST2 Signaling in Tumor Microenvironment [PDF]

open access: yesJournal of Interferon & Cytokine Research, 2019
Interleukin-33 (IL-33) is one of the members of the IL-1 family of cytokines and a ligand of ST2 and IL-1 receptor accessory protein (IL-1RAcP) that is known to affect Th2 inflammatory response with partial effects on Th1 responses. This cytokine is released by epithelial and smooth muscle cells of the airway system during their injury by several ...
Jaewoo, Hong   +2 more
openaire   +2 more sources

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy